Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE)

Emmanuelle Duceppe, Salim Yusuf, Vikas Tandon, Reitze Rodseth, Bruce M. Biccard, Denis Xavier, Wojciech Szczeklik, Christian S. Meyhoff, Maria Grazia Franzosi, Jessica Vincent, Sadeesh K. Srinathan, Joel Parlow, Patrick Magloire, John Neary, Mangala Rao, Navneet K. Chaudhry, Bongani Mayosi, Miriam de Nadal, Ekaterine Popova, Juan Carlos VillarFernando Botto, Otavio Berwanger, Gordon Guyatt, John W. Eikelboom, Daniel I. Sessler, Clive Kearon, Shirley Pettit, Stuart J. Connolly, Mukul Sharma, Shrikant I. Bangdiwala, P. J. Devereaux

Research output: Articles / NotesScientific Articlepeer-review

23 Scopus citations


Background: Worldwide approximately 200 million adults undergo major surgery annually, of whom 8 million are estimated to suffer a myocardial injury after noncardiac surgery (MINS). There is currently no trial data informing the management of MINS. Antithrombotic agents such as direct oral anticoagulants might prevent major vascular complications in patients with MINS. Methods: The Management of Myocardial Injury After Noncardiac Surgery (MANAGE) trial is a large international blinded randomized controlled trial of dabigatran vs placebo in patients who suffered MINS. We used a partial factorial design to also determine the effect of omeprazole vs placebo in reducing upper gastrointestinal bleeding and complications. Both study drugs were initiated in eligible patients within 35 days of suffering MINS and continued for a maximum of 2 years. The primary outcome is a composite of major vascular complications for the dabigatran trial and a composite of upper gastrointestinal complications for the omeprazole trial. We present the rationale and design of the trial and baseline characteristics of enrolled patients. Results: The trial randomized 1754 patients between January 2013 and July 2017. Patients’ mean age was 69.9 years, 51.1% were male, 14.3% had a history of peripheral artery disease, 6.6% had a history of stroke or transient ischemic attack, 12.9% had a previous myocardial infarction, and 26.0% had diabetes. The diagnosis of MINS was on the basis of an isolated ischemic troponin elevation in 80.4% of participants. Conclusion: MANAGE is the first randomized controlled trial to evaluate a potential treatment of patients who suffered MINS.

Original languageEnglish
Pages (from-to)295-302
Number of pages8
JournalCanadian Journal of Cardiology
Issue number3
StatePublished - Mar 2018


Dive into the research topics of 'Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE)'. Together they form a unique fingerprint.

Cite this